CTBO (Cantabio Pharmaceuticals) Operating Margin %: 0.00% (As of Dec. 2018)


What is Cantabio Pharmaceuticals Operating Margin %?

Cantabio Pharmaceuticals CTBO Operating Margin % is 0.00% as of Dec. 2018.

Operating Margin % is calculated as Operating Income divided by its Revenue. Cantabio Pharmaceuticals's Operating Income for the three months ended in Dec. 2018 was $-0.24 Mil. Cantabio Pharmaceuticals's Revenue for the three months ended in Dec. 2018 was $0.00 Mil. Therefore, Cantabio Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2018 was 0.00%.

The historical rank and industry rank for Cantabio Pharmaceuticals's Operating Margin % or its related term are showing as below:


CTBO's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.83
* Ranked among companies with meaningful Operating Margin % only.

Cantabio Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Cantabio Pharmaceuticals's Operating Income for the three months ended in Dec. 2018 was $-0.24 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2018 was $-1.33 Mil.


Cantabio Pharmaceuticals  (OTCPK:CTBO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cantabio Pharmaceuticals Operating Margin % Related Terms


Cantabio Pharmaceuticals Operating Margin % Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Operating Margin % Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Operating Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CTBO vs TNTY, ETNI, NTRR: Operating Margin % Comparison

For the Biotechnology subindustry, Cantabio Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantabio Pharmaceuticals Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's Operating Margin % falls into.



Cantabio Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cantabio Pharmaceuticals's Operating Margin % for the fiscal year that ended in Mar. 2018 is calculated as

Operating Margin %=Operating Income (A: Mar. 2018 ) / Revenue (A: Mar. 2018 )
=-1.349 / 0
= %

Cantabio Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2018 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2018 ) / Revenue (Q: Dec. 2018 )
=-0.24 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Cantabio Pharmaceuticals (CTBO) has a Operating Margin % of 0.00% as of Dec. 2018. Operating margin is the ratio of total operating income to net sales. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Operating Margin % too high?
Cantabio Pharmaceuticals' current Operating Margin % is 0.00%.
How does Cantabio Pharmaceuticals' Operating Margin % compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Operating Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Operating Margin % is 0.00% as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.